The regulatory roles of estrogen in carcinogenesis: An overview

Phytopharmaceuticals in Cancer Chemoprevention

Volumn , Issue , 2004, Pages 105-122

  Banerjee, Sushanta K ^a,b   Islam, Aminul ^a,b   Banerjee, Snigdha ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867895509     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (162)

1. Norman, A.W. and Litwack, G., Estrogens and Progestins, Hormones, Academic Press, New York, 1997, pp. 361-386.
2. Travis, R.C. and Key, T.J., Oestrogen exposure and breast cancer risk, Breast Cancer Res., 5, 239-247, 2003.
3. Parl, F.F., Estrogen Synthesis and Metabolism: Estrogens, Estrogen Receptor and Breast Cancer, IOS Press, Washington, DC, 2002, pp. 21-56.
4. Beato, M., Gene regulation by steroid hormones, Cell, 56, 335-344, 1989.
5. Manolagas, S.C. and Kousteni, S., Perspective: nonreproductive sites of action of reproductive hormones, Endocrinology, 142, 2200-2204, 2001.
6. Kousteni, S., Bellido, T., Plotkin, L.I., O’Brien, C.A., Bodenner, D.L., Han. L., Han, K., DiGregorio, G.B., Katzenellenbogen, J.A., Katzenellenbogen, B.S., Roberson, P.K., Weinstein, R.S., Jilka, R.L., and Manolagas, S.C., Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity, Cell, 104, 719-730, 2001.
7. Norbury, R., Cutter, W.J., Compton, J., Robertson, D.M., Craig, M., Whitehead, M., and Murphy, D.G., The neuroprotective effects of estrogen on the aging brain, Exp. Gerontol., 38, 109-117, 2003.
8. Hodis, H.N., Mack, W.J., Azen, S.P., Lobo, R.A., Shoupe, D., Mahrer, P.R., Faxon, D.P., Cashin-Hemphill, L., Sanmarco, M.E., French, W.J., Shook, T.L., Gaarder, T.D., Mehra, A.O., Rabbani, R., Sevanian, A., Shil, A.B., Torres, M., Vogelbach, K.H., and Selzer, R.H., Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women, New England J. Med., 349, 535-545, 2003.
9. Hodis, H.N., Mack, W.J., and Lobo, R., What is the cardioprotective role of hormone replacement therapy?, Curr. Atheroscler. Rep., 5, 56-66, 2003.
10. Mack, W.J., Hameed, A.B., Xiang, M., Roy, S., Slater, C.C., Stanczyk, F.Z., Lobo, R.A., Liu, C., Liu, C., and Hodis, H.N., Does elevated body mass modify the influence of postmenopausal estrogen replacement on atherosclerosis progression: results from the estrogen in the prevention of atherosclerosis trial, Atherosclerosis, 168, 91-98, 2003.
11. Henderson, B.E., Ross, R.K., Lobo, R.A., Pike, M.C., and Mack, T.M., Re-evaluating the role of progestogen therapy after the menopause, Fertil. Steril., 49, 9S-15S, 1988.
12. Henderson, B.E., Ross, R., and Bernstein, L., Estrogens as a cause of human cancer: the Richard and Hinda Rosenthal Foundation award lecture, Cancer Res., 48, 246-253, 1988.
13. Banerjee, S.K., Sarkar, D.K., Weston, A.P., De, A., and Campbell, D.R., Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis, Carcinogenesis, 18, 1155-1161, 1997.
14. Li, J.J., Gonzalez, A., Banerjee, S., Banerjee, S.K., and Li, S.A., Estrogen carcinogenesis in the hamster kidney: role of cytotoxicity and cell proliferation, Environ. Health Perspect., 101 (Suppl. 5), 259-264, 1993.
15. Liehr, J.G., Is estradiol a genotoxic mutagenic carcinogen?, Endocr. Rev., 21, 40-54, 2000.
16. Yager, J.D. and Liehr, J.G., Molecular mechanisms of estrogen carcinogenesis, Annu. Rev. Pharmacol. Toxicol., 36, 203-232, 1996.
17. Liehr, J.G., Genotoxic effects of estrogens, Mutat. Res., 238, 269-276, 1990.
18. Roy, D. and Liehr, J.G., Inhibition of estrogen-induced kidney carcinogenesis in Syrian hamsters by modulators of estrogen metabolism, Carcinogenesis, 11, 567-570, 1990.
19. Li, J.J. and Li, S.A., Estrogen carcinogenesis in the hamster kidney: a hormone-driven multistep process, Prog. Clin. Biol. Res., 394, 255-267, 1996.
20. Li, J.J. and Li, S.A., Estrogen carcinogenesis in hamster tissues: a critical review, Endocr. Rev., 11, 524-531, 1990.
21. Cavalieri, E., Frenkel, K., Liehr, J.G., Rogan, E., and Roy, D., Estrogens as endogenous genotoxic agents: DNA adducts and mutations, J. Natl. Cancer Inst. Monogr., 75-94, 2000.
22. Moolgavkar, S.H., Carcinogenesis modeling: from molecular biology to epidemiology, Annu. Rev. Public Health, 7, 151-169, 1986.
23. Moolgavkar, S.H., Hormones and multistage carcinogenesis, Cancer Surv., 5, 635-648, 1986.
24. Key, T.J. and Pike, M.C., The role of oestrogens and progestagens in the epidemiology and prevention of breast cancer, Eur. J. Cancer Clin. Oncol., 24, 29-43, 1988.
25. Banerjee, S.K., Banerjee, S., Li, S.A., and Li, J.J., Induction of chromosome aberrations in Syrian hamster renal cortical cells by various estrogens, Mutat. Res., 311, 191-197, 1994.
26. Browder, T., Folkman, J., and Pirie-Shepherd, S., The hemostatic system as a regulator of angiogenesis, J. Biol. Chem., 275, 1521-1524, 2000.
27. Shelhamer, J.H., Volkman, D.J., Parrillo, J.E., Lawley, T.J., Johnston, M.R., and Fauci, A.S., Takayasu’s arteritis and its therapy, Ann. Intern. Med., 103, 121-126, 1985.
28. Ansar, A.S., Penhale, W.J., and Talal, N., Sex hormones, immune responses, and autoimmune diseases:mechanisms of sex hormone action, Am. J. Pathol., 121, 531-551, 1985.
29. Cullinan-Bove, K. and Koos, R.D., Vascular endothelial growth factor/vascular permeability factor expression in the rat uterus: rapid stimulation by estrogen correlates with estrogen-induced increases in uterine capillary permeability and growth, Endocrinology, 133, 829-837, 1993.
30. Johns, A., Freay, A.D., Fraser, W., Korach, K.S., and Rubanyi, G.M., Disruption of estrogen receptor gene prevents 17 beta estradiol-induced angiogenesis in transgenic mice, Endocrinology, 137, 4511-4513, 1996.
31. Toi, M., Kashitani, J., and Tominaga, T., Tumor angiogenesis is an independent prognostic indicator in primary breast carcinoma, Int. J. Cancer, 55, 371-374, 1993.
32. Vartanian, R.K. and Weidner, N., Correlation of intratumoral endothelial cell proliferation with microvessel density (tumor angiogenesis) and tumor cell proliferation in breast carcinoma, Am. J. Pathol., 144, 1188-1194, 1994.
33. Banerjee, S.K., Campbell, D.R., Weston, A.P., and Banerjee, D.K., Biphasic estrogen response on bovine adrenal medulla capillary endothelial cell adhesion, proliferation and tube formation, Mol. Cell. Biochem., 177, 97-105, 1997.
34. Iruela-Arispe, M.L., Porter, P., Bornstein, P., and Sage, E.H., Thrombospondin-1, an inhibitor of angiogenesis, is regulated by progesterone in the human endometrium, J. Clin. Invest., 97, 403-412, 1996.
35. Gagliardi, A.R., Hennig, B., and Collins, D.C., Antiestrogens inhibit endothelial cell growth stimulated by angiogenic growth factors, Anticancer Res., 16, 1101-1106, 1996.
36. Fox, J.E., Starcevic, M., Kow, K.Y., Burow, M.E., and McLachlan, J.A., Nitrogen fixation: endocrine disrupters and flavonoid signalling, Nature, 413, 128-129, 2001.
37. Welshons, W.V., Thayer, K.A., Judy, B.M., Taylor, J.A., Curran, E.M., and Vom Saal, F.S., Large effects from small exposures, I: mechanisms for endocrine-disrupting chemicals with estrogenic activity, Environ. Health Perspect., 111, 994-1006, 2003.
38. Daston, G.P., Cook, J.C., and Kavlock, R.J., Uncertainties for endocrine disrupters: our view on progress, Toxicol. Sci., 74, 245-252, 2003.
39. Buchner, V., Environmental endocrine disrupting chemicals, Rev. Environ. Health, 17, 249-252, 2002.
40. Singleton, D.W. and Khan, S.A., Xenoestrogen exposure and mechanisms of endocrine disruption, Front Biosci., 8, s110-s118, 2003.
41. Quesada, I., Fuentes, E., Viso-Leon, M.C., Soria, B., Ripoll, C., and Nadal, A., Low doses of the endocrine disruptor bisphenol-A and the native hormone 17beta-estradiol rapidly activate transcription factor CREB, FASEB J., 16, 1671-1673, 2002.
42. Takeshita, A., Koibuchi, N., Oka, J., Taguchi, M., Shishiba, Y., and Ozawa, Y., Bisphenol A, an environmental estrogen, activates the human orphan nuclear receptor, steroid and xenobiotic receptormediated transcription, Eur. J. Endocrinol., 145, 513-517, 2001.
43. Gore, A.C., Environmental toxicant effects on neuroendocrine function, Endocrine, 14, 235-246, 2001.
44. Janssens, J.P., Van Hecke, E., Geys, H., Bruckers, L., Renard, D., and Molenberghs, G., Pesticides and mortality from hormone-dependent cancers, Eur. J. Cancer Prev., 10, 459-467, 2001.
45. Cooper, R.L. and Kavlock, R.J., Endocrine disruptors and reproductive development: a weight-ofevidence overview, J. Endocrinol., 152, 159-166, 1997.
46. Safe, S.H., Pallaroni, L., Yoon, K., Gaido, K., Ross, S., and McDonnell, D., Problems for risk assessment of endocrine-active estrogenic compounds, Environ. Health Perspect., 110 (Suppl. 6), 925-929, 2002.
47. Horn-Ross, P.L., John, E.M., Canchola, A.J., Stewart, S.L., and Lee, M.M., Phytoestrogen intake and endometrial cancer risk, J. Natl. Cancer Inst., 95, 1158-1164, 2003.
48. Watanabe, S., Uesugi, S., Zhuo, X., and Kimira, M., Phytoestrogen and cancer prevention, Gan To Kagaku Ryoho, 30, 902-908, 2003.
49. Tsutsui, T., Tamura, Y., Yagi, E., Someya, H., Hori, I., Metzler, M., and Barrett, J.C., Cell-transforming activity and mutagenicity of 5 phytoestrogens in cultured mammalian cells, Int. J. Cancer, 105, 312-320, 2003.
50. Adlercreutz, H., Phytoestrogens and breast cancer, J. Steroid Biochem. Mol. Biol., 83, 113-118, 2002.
51. Mishra, S.I., Dickerson, V., and Najm, W., Phytoestrogens and breast cancer prevention: what is the evidence?, Am. J. Obstet. Gynecol., 188, S66-S70, 2003.
52. Albertazzi, P. and Purdie, D., The nature and utility of the phytoestrogens: a review of the evidence, Maturitas, 42, 173-185, 2002.
53. Chen, W.F., Huang, M.H., Tzang, C.H., Yang, M., and Wong, M.S., Inhibitory actions of genistein in human breast cancer (MCF-7) cells, Biochim. Biophys. Acta, 1638, 187-196, 2003.
54. Fox, J.E., Burow, M.E., and McLachlan, J.A., Symbiotic gene activation is interrupted by endocrine disrupting chemicals, Scientific World J., 1, 653-655, 2001.
55. Levenson, A.S., Gehm, B.D., Pearce, S.T., Horiguchi, J., Simons, L.A., Ward, III, J.E., Jameson, J.L., and Jordan, V.C., Resveratrol acts as an estrogen receptor (ER) agonist in breast cancer cells stably transfected with ER alpha, Int. J. Cancer, 104, 587-596, 2003.
56. Mueller, S.O., Kling, M., Arifin, F.P., Mecky, A., Duranti, E., Shields-Botella, J., Delansorne, R., Broschard, T., and Kramer, P.J., Activation of estrogen receptor alpha and ERbeta by 4-methylbenzylidene- camphor in human and rat cells: comparison with phyto- and xenoestrogens, Toxicol. Lett., 142, 89-101, 2003.
57. Rickard, D.J., Monroe, D.G., Ruesink, T.J., Khosla, S., Riggs, B.L., and Spelsberg, T.C., Phytoestrogen genistein acts as an estrogen agonist on human osteoblastic cells through estrogen receptors alpha and beta, J. Cell. Biochem., 89, 633-646, 2003.
58. IARC, Monographs on the Evaluation of Carcinogenic Risks to Human: Hormonal Contraception and Post Menopausal Hormone Therapy, International Agency for Research on Cancer, Lyons, France, 1999.
59. Tsutsui, T. and Barrett, J.C., Neoplastic transformation of cultured mammalian cells by estrogens and estrogenlike chemicals, Environ. Health Perspect., 105 (Suppl. 3), 619-624, 1997.
60. Yagi, E., Barrett, J.C., and Tsutsui, T., The ability of four catechol estrogens of 17beta-estradiol and estrone to induce DNA adducts in Syrian hamster embryo fibroblasts, Carcinogenesis, 22, 1505-1510, 2001.
61. Tsutsui, T., Tamura, Y., Yagi, E., and Barrett, J.C., Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using Syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites, Int. J. Cancer, 86, 8-14, 2000.
62. Tsutsui, T., Tamura, Y., Hagiwara, M., Miyachi, T., Hikiba, H., Kubo, C., and Barrett, J.C., Induction of mammalian cell transformation and genotoxicity by 2-methoxyestradiol, an endogenous metabolite of estrogen, Carcinogenesis, 21, 735-740, 2000.
63. Kyrtopoulos, S.A., Anderson, L.M., Chhabra, S.K., Souliotis, V.L., Pletsa, V., Valavanis, C., and Georgiadis, P., DNA adducts and the mechanism of carcinogenesis and cytotoxicity of methylating agents of environmental and clinical significance, Cancer Detection Prev., 21, 391-405, 1997.
64. Kyrtopoulos, S.A., DNA adducts in humans after exposure to methylating agents, Mutat. Res., 405, 135-143, 1998.
65. Huseby, R.A., Demonstration of a direct carcinogenic effect of estradiol on Leydig cells of the mouse, Cancer Res., 40, 1006-1013, 1980.
66. Highman, B., Roth, S.I., and Greenman, D.L., Osseous changes and osteosarcomas in mice continuously fed diets containing diethylstilbestrol or 17beta-estradiol, J. Natl. Cancer Inst., 67, 653-662, 1981.
67. Son, D.S., Roby, K.F., Rozman, K.K., and Terranova, P.F., Estradiol enhances and estriol inhibits the expression of CYP1A1 induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin in a mouse ovarian cancer cell line, Toxicology, 176, 229-243, 2002.
68. Han, B.S., Fukamachi, K., Takasuka, N., Ohnishi, T., Maeda, M., Yamasaki, T., and Tsuda, H., Inhibitory effects of 17beta-estradiol and 4-n-octylphenol on 7,12-dimethylbenz[a]anthracene-induced mammary tumor development in human c-Ha-ras proto-oncogene transgenic rats, Carcinogenesis, 23, 1209-1215, 2002.
69. Shull, J.D., Spady, T.J., Snyder, M.C., Johansson, S.L., and Pennington, K.L., Ovary-intact, but not ovariectomized female ACI rats treated with 17beta-estradiol rapidly develop mammary carcinoma, Carcinogenesis, 18, 1595-1601, 1997.
70. Liehr, J.G., Stancel, G.M., Chorich, L.P., Bousfield, G.R., and Ulubelen, A.A., Hormonal carcinogenesis:separation of estrogenicity from carcinogenicity, Chem. Biol. Interact., 59, 173-184, 1986.
71. Bhat, H.K., Calaf, G., Hei, T.K., Loya, T., and Vadgama, J.V., Critical role of oxidative stress in estrogen-induced carcinogenesis, Proc. Natl. Acad. Sci. USA, 100, 3913-3918, 2003.
72. Cavalieri, E.L., Stack, D.E., Devanesan, P.D., Todorovic, R., Dwivedy, I., Higginbotham, S., Johansson, S.L., Patil, K.D., Gross, M.L., Gooden, J.K., Ramanathan, R., Cerny, R.L., and Rogan, E.G., Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators, Proc. Natl. Acad. Sci. USA, 94, 10937-10942, 1997.
73. Li, S., Washburn, K.A., Moore, R., Uno, T., Teng, C., Newbold, R.R., McLachlan, J.A., and Negishi, M., Developmental exposure to diethylstilbestrol elicits demethylation of estrogen-responsive lactoferrin gene in mouse uterus, Cancer Res., 57, 4356-4359, 1997.
74. Liehr, J.G., Role of DNA adducts in hormonal carcinogenesis, Regul. Toxicol. Pharmacol., 32, 276-282, 2000.
75. Berger, J. and Daxenbichler, G., DNA methylation of nuclear receptor genes: possible role in malignancy, J. Steroid Biochem. Mol. Biol., 80, 1-11, 2002.
76. Li, S., Ma, L., Chiang, T., Burow, M., Newbold, R.R., Negishi, M., Barrett, J.C., and McLachlan, J.A., Promoter CpG methylation of Hox-a10 and Hox-a11 in mouse uterus not altered upon neonatal diethylstilbestrol exposure, Mol. Carcinog., 32, 213-219, 2001.
77. Li, S., Hursting, S.D., Davis, B.J., McLachlan, J.A., and Barrett, J.C., Environmental exposure, DNA methylation, and gene regulation: lessons from diethylstilbestrol-induced cancers, Ann. N.Y. Acad. Sci., 983, 161-169, 2003.
78. Jost, J.P. and Saluz, H.P., Steroid hormone dependent changes in DNA methylation and its significance for the activation or silencing of specific genes, EXS, 64, 425-451, 1993.
79. Ginger, M.R., Gonzalez-Rimbau, M.F., Gay, J.P., and Rosen, J.M., Persistent changes in gene expression induced by estrogen and progesterone in the rat mammary gland, Mol. Endocrinol., 15, 1993-2009, 2001.
80. Castro-Rivera, E., Samudio, I., and Safe, S., Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements, J. Biol. Chem., 276, 30853-30861, 2001.
81. Henderson, B.E. and Feigelson, H.S., Hormonal carcinogenesis, Carcinogenesis, 21, 427-433, 2000.
82. Mollerup, S., Jorgensen, K., Berge, G., and Haugen, A., Expression of estrogen receptors alpha and beta in human lung tissue and cell lines, Lung Cancer, 37, 153-159, 2002.
83. Steiner, M.S. and Raghow, S., Antiestrogens and selective estrogen receptor modulators reduce prostate cancer risk, World J. Urol., 21, 31-36, 2003.
84. Endogenous Hormones and Breast Cancer Collaborative Group, Endogenous sex hormones and breast cancer in post-menopausal women: reanalysis on nine prospective studies, J. Natl. Cancer Inst., 94, 606-616, 2002.
85. Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., and Boyle, P., Overview of the main outcomes in breast-cancer prevention trials, Lancet, 361, 296-300, 2003.
86. MacDonald, P.C., Edman, C.D., Hemsell, D.L., Porter, J.C., Siiteri, and P.K., Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer, Am. J. Obstet. Gynecol., 130, 448-455, 1978.
87. Kelsey, J.L. and Horn-Ross, P.L., Breast cancer: magnitude of the problem and descriptive epidemiology, Epidemiol. Rev., 15, 7-16, 1993.
88. Kelsey, J.L., Breast cancer epidemiology: summary and future directions, Epidemiol. Rev., 15, 256-263, 1993.
89. Hoffman, S., Grisso, J.A., Kelsey, J.L., Gammon, M.D., and O’Brien, L.A., Parity, lactation and hip fracture, Osteoporos. Int., 3, 171-176, 1993.
90. Lipsett, M.B., Estrogen use and cancer risk, J. Am. Med. Assoc., 237, 1112-1115, 1977.
91. Russo, J., Hu, Y.F., Tahin, Q., Mihaila, D., Slater, C., Lareef, M.H., and Russo, I.H., Carcinogenicity of estrogens in human breast epithelial cells, APMIS, 109, 39-52, 2001.
92. Laitman, C.J., DES exposure and the aging woman: mothers and daughters, Curr. Womens Health Rep., 2, 390-393, 2002.
93. Titus-Ernstoff, L., Hatch, E.E., Hoover, R.N., Palmer, J., Greenberg, E.R., Ricker, W., Kaufman, R., Noller, K., Herbst, A.L., Colton, T., and Hartge, P., Long-term cancer risk in women given diethylstilbestrol (DES) during pregnancy, Br. J. Cancer, 84, 126-133, 2001.
94. Duan, R., Xie, W., Burghardt, R.C., and Safe, S., Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1, J. Biol. Chem., 276, 11590-11598, 2001.
95. Perillo, B., Sasso, A., Abbondanza, C., and Palumbo, G., 17Beta-estradiol inhibits apoptosis in MCF-7 cells, inducing bcl-2 expression via two estrogen-responsive elements present in the coding sequence, Mol. Cell. Biol., 20, 2890-2901, 2000.
96. Urban, G., Golden, T., Aragon, I.V., Scammell, J.G., Dean, N.M., Honkanen, R.E., Identification of an estrogen-inducible phosphatase (PP5) that converts MCF-7 human breast carcinoma cells into an estrogen-independent phenotype when expressed constitutively, J. Biol. Chem., 276, 27638-27646, 2001.
97. Burow, M.E., Weldon, C.B., Tang, Y., McLachlan, J.A., and Beckman, B.S., Oestrogen-mediated suppression of tumour necrosis factor alpha-induced apoptosis in MCF-7 cells: subversion of Bcl-2 by anti-oestrogens, J. Steroid Biochem. Mol. Biol., 78, 409-418, 2001.
98. Krepinsky, J., Ingram, A.J., James, L., Ly, H., Thai, K., Cattran, D.C., Miller, J.A., and Scholey, J.W., 17Beta-estradiol modulates mechanical strain-induced MAPK activation in mesangial cells, J. Biol. Chem., 277, 9387-9394, 2002.
99. Banerjee, S., Saxena, N., Sengupta, K., Tawfik, O., Mayo, M.S., and Banerjee, S.K., WISP-2 gene in human breast cancer: estrogen and progesterone inducible expression and regulation of tumor cell proliferation, Neoplasia, 5, 63-73, 2003.
100. Folkman, J., Angiogenesis and angiogenesis inhibition: an overview, EXS, 79, 1-8, 1997.
101. Folkman, J., Angiogenesis: initiation and modulation, Symp. Fundam. Cancer Res., 36, 201-208, 1983.
102. Risau, W., Angiogenic growth factors, Prog. Growth Factor Res., 2, 71-79, 1990.
103. Bergers, G. and Benjamin, L.E., Angiogenesis: tumorigenesis and the angiogenic switch, Nat. Rev. Cancer, 3, 401-410, 2003.
104. Liotta, L.A. and Stetler-Stevenson, W.G., Tumor invasion and metastasis: an imbalance of positive and negative regulation, Cancer Res., 51, 5054s-5059s, 1991.
105. Hanahan, D. and Folkman, J., Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis, Cell, 86, 353-364, 1996.
106. Cockerill, G.W., Gamble, J.R., and Vadas, M.A., Angiogenesis: models and modulators, Int. Rev. Cytol., 159, 113-160, 1995.
107. Soares, R., Guo, S., Russo, J., and Schmitt, F., Role of the estrogen antagonist ICI 182,780 in vessel assembly and apoptosis of endothelial cells, Ultrastruct. Pathol., 27, 33-39, 2003.
108. McNamara, D.A., Harmey, J., Wang, J.H., Kay, E., Walsh, T.N., and Bouchier-Hayes, D.J., Tamoxifen inhibits endothelial cell proliferation and attenuates VEGF-mediated angiogenesis and migration in vivo, Eur. J. Surg. Oncol., 27, 714-718, 2001.
109. Calabrese, E.J., Estrogen and related compounds: biphasic dose responses, Crit. Rev. Toxicol., 31, 503-515, 2001.
110. Marson, L.P., Kurian, K.M., Miller, W.R., and Dixon, J.M., The effect of tamoxifen on breast tumour vascularity, Breast Cancer Res. Treat., 66, 9-15, 2001.
111. Banerjee, S., Saxena, N., Sengupta, K., and Banerjee, S.K., 17Alpha-estradiol-induced VEGF-A expression in rat pituitary tumor cells is mediated through ER independent but PI3K-Akt dependent signaling pathway, Biochem. Biophys. Res. Commun., 300, 209-215, 2003.
112. Banerjee, S.K., Zoubine, M.N., Tran, T.M., Weston, A.P., and Campbell, D.R., Overexpression of vascular endothelial growth factor164 and its co-receptor neuropilin-1 in estrogen-induced rat pituitary tumors and GH3 rat pituitary tumor cells, Int. J. Oncol., 16, 253-260, 2000.
113. Sengupta, K., Banerjee, S., Saxena, N., and Banerjee, S.K., Estradiol-induced vascular endothelial growth factor-A expression in breast tumor cells is biphasic and regulated by estrogen receptor-alpha dependent pathway, Int. J. Oncol., 22, 609-614, 2003.
114. Maity, A., Sall, W., Koch, C.J., Oprysko, P.R., and Evans, S.M., Low pO2 and beta-estradiol induce VEGF in MCF-7 and MCF-7-5C cells: relationship to in vivo hypoxia, Breast Cancer Res. Treat., 67, 51-60, 2001.
115. Ruohola, J.K., Valve, E.M., Karkkainen, M.J., Joukov, V., Alitalo, K., and Harkonen, P.L., Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells, Mol. Cell. Endocrinol., 149, 29-40, 1999.
116. Mueller, M.D., Vigne, J.L., Minchenko, A., Lebovic, D.I., Leitman, D.C., and Taylor, R.N., Regulation of vascular endothelial growth factor (VEGF) gene transcription by estrogen receptors alpha and beta, Proc. Natl. Acad. Sci. USA, 97, 10972-10977, 2000.
117. Ochoa, A.L., Mitchner, N.A., Paynter, C.D., Morris, R.E., and Ben-Jonathan, N., Vascular endothelial growth factor in the rat pituitary: differential distribution and regulation by estrogen, J. Endocrinol., 165, 483-492, 2000.
118. Banerjeei, S.K., Zoubine, M.N., Sarkar, D.K., Weston, A.P., Shah, J.H., and Campbell, D.R., 2-Methoxyestradiol blocks estrogen-induced rat pituitary tumor growth and tumor angiogenesis:possible role of vascular endothelial growth factor, Anticancer Res., 20, 2641-2645, 2000.
119. Banerjee, S.N., Sengupta, K., Banerjee, S., Saxena, N., and Banerjee, S.K., 2-Methoxyestradiol exhibits a biphasic effect on VEGF-A in tumor cells and upregulation is mediated through ER-α: a possible signaling pathway associated with the impact of 2-ME2 on proliferative cells, Neoplasia, 5, 417-426, 2003.
120. Menendez, J.A., Mehmi, I., Griggs, D.W., and Lupu, R., The angiogenic factor CYR61 in breast cancer: molecular pathology and therapeutic perspectives, Endocr. Relat. Cancer, 10, 141-152, 2003.
121. Lincoln, D.W., Phillips, P.G., and Bove, K., Estrogen-induced Ets-1 promotes capillary formation in an in vitro tumor angiogenesis model, Breast Cancer Res. Treat., 78, 167-178, 2003.
122. Albrecht, E.D. and Pepe, G.J., Steroid hormone regulation of angiogenesis in the primate endometrium, Front Biosci., 8, d416-d429, 2003.
123. Dabrosin, C., Palmer, K., Muller, W.J., and Gauldie, J., Estradiol promotes growth and angiogenesis in polyoma middle T transgenic mouse mammary tumor explants, Breast Cancer Res. Treat., 78, 1-6, 2003.
124. Fukuro, H., Mogi, C., Yokoyama, K., and Inoue, K., Change in expression of basic fibroblast growth factor mRNA in a pituitary tumor clonal cell line, Endocr. Pathol., 14, 145-149, 2003.
125. Millauer, B., Shawver, L.K., Plate, K.H., Risau, W., and Ullrich, A., Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant, Nature, 367, 576-579, 1994.
126. Jilma, B., Eichler, H.G., Breiteneder, H., Wolzt, M., Aringer, M., Graninger, W., Rohrer, C., Veitl, M., and Wagner, O.F., Effects of 17 beta-estradiol on circulating adhesion molecules, J. Clin. Endocrinol. Metab., 79, 1619-1624, 1994.
127. Aziz, K.E. and Wakefield, D., Modulation of endothelial cell expression of ICAM-1, E-selectin, and VCAM-1 by beta-estradiol, progesterone, and dexamethasone, Cell. Immunol., 167, 79-85, 1996.
128. Brooks, P.C., Cell adhesion molecules in angiogenesis, Cancer Metastasis Rev., 15, 187-194, 1996.
129. Sengupta, K., Banerjee, S., Saxena, N., and Banerjee, S.K., Estrogen-induced down regulation of thrombospondin-1 in rat pituitary tumor cells and in rat pituitaries may be associated with estrogeninduced tumor cell growth and angiogenesis, Proc. Am. Assoc. Cancer Res., 44, 103, 2003.
130. Petrangeli, E., Lubrano, C., Ortolani, F., Ravenna, L., Vacca, A., Sciacchitano, S., Frati, L., and Gulino, A., Estrogen receptors: new perspectives in breast cancer management, J. Steroid Biochem. Mol. Biol., 49, 327-331, 1994.
131. Parl, F.F., Estrogen Receptor Expression in Breast Cancer: Estrogens, Estrogen Receptor and Breast Cancer, IOS Press, Washington, DC, 2002, pp. 135-204.
132. Parl, F.F., Estrogen Receptor: Estrogens, Estrogen Receptor and Breast Cancer, IOS Press, Ohmsha, Washington, DC, 2002, pp. 57-110.
133. Levin, E.R., Cell localization, physiology, and nongenomic actions of estrogen receptors, J. Appl. Physiol., 91, 1860-1867, 2001.
134. Collins, P. and Webb, C., Estrogen hits the surface, Nat. Med., 5, 1130-1131, 1999.
135. Levin, E.R., Bidirectional signaling between the estrogen receptor and the epidermal growth factor receptor, Mol. Endocrinol., 17, 309-317, 2003.
136. Valentine, J.E., Kalkhoven, E., White, R., Hoare, S., and Parker, M.G., Mutations in the estrogen receptor ligand binding domain discriminate between hormone-dependent transactivation and transrepression, J. Biol. Chem., 275, 25322-25329, 2000.
137. Pedram, A., Razandi, M., Aitkenhead, M., Hughes, C.C., and Levin, E.R., Integration of the nongenomic and genomic actions of estrogen: membrane-initiated signaling by steroid to transcription and cell biology, J. Biol. Chem., 277, 50768-50775, 2002.
138. Kelly, M.J. and Levin, E.R., Rapid actions of plasma membrane estrogen receptors, Trends Endocrinol. Metab., 12, 152-156, 2001.
139. Goetz, R.M., Thatte, H.S., Prabhakar, P., Cho, M.R., Michel, T., and Golan, D.E., Estradiol induces the calcium-dependent translocation of endothelial nitric oxide synthase, Proc. Natl. Acad. Sci. USA, 96, 2788-2793, 1999.
140. Le, M.V., Grosse, B., and Lieberherr, M., Phospholipase C beta and membrane action of calcitriol and estradiol, J. Biol. Chem., 272, 11902-11907, 1997.
141. Razandi, M., Alton, G., Pedram, A., Ghonshani, S., Webb, P., and Levin, E.R., Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane, Mol. Cell. Biol., 23, 1633-1646, 2003.
142. Razandi, M., Pedram, A., Greene, G.L., and Levin, E.R., Cell membrane and nuclear estrogen receptors (ERs) originate from a single transcript: studies of ERalpha and ERbeta expressed in Chinese hamster ovary cells, Mol. Endocrinol., 13, 307-319, 1999.
143. Kumar, R., Wang, R.A., Mazumdar, A., Talukder, A.H., Mandal, M., Yang, Z., Bagheri-Yarmand, R., Sahin, A., Hortobagyi, G., Adam, L., Barnes, C.J., and Vadlamudi, R.K., A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm, Nature, 418, 654-657, 2002.
144. Gee, A.C., Carlson, K.E., Martini, P.G., Katzenellenbogen, B.S., and Katzenellenbogen, J.A., Coactivator peptides have a differential stabilizing effect on the binding of estrogens and antiestrogens with the estrogen receptor, Mol. Endocrinol., 13, 1912-1923, 1999.
145. Greschik, H., Wurtz, J.M., Sanglier, S., Bourguet, W., van Dorsselaer, A., Moras, D., and Renaud, J.P., Structural and functional evidence for ligand-independent transcriptional activation by the estrogenrelated receptor 3, Mol. Cell, 9, 303-313, 2002.
146. This, P., De La, R.A., Clough, K., Fourquet, A., and Magdelenat, H., Phytoestrogens after breast cancer, Endocr. Relat. Cancer, 8, 129-134, 2001.
147. McLachlan, J.A. and Newbold, R.R., Estrogens and development, Environ. Health Perspect., 75, 25-27, 1987.
148. Jones, L.A. and Hajek, R.A., Effects of estrogenic chemicals on development, Environ. Health Perspect., 103 (Suppl. 7), 63-67, 1995.
149. Kohlmeier, L., Simonsen, N., and Mottus, K., Dietary modifiers of carcinogenesis, Environ. Health Perspect., 103 (Suppl. 8), 177-184, 1995.
150. Coffey, D.S., Similarities of prostate and breast cancer: evolution, diet, and estrogens, Urology, 57, 31-38, 2001.
151. Golden, R.J., Noller, K.L., Titus-Ernstoff, L., Kaufman, R.H., Mittendorf, R., Stillman, R., and Reese, E.A., Environmental endocrine modulators and human health: an assessment of the biological evidence, Crit. Rev. Toxicol., 28, 109-227, 1998.
152. Anderson, J.W., Dietary fibre, complex carbohydrate and coronary artery disease, Can. J. Cardiol., 11 (Suppl. G), 55G-62G, 1995.
153. Potter, J.D. and Steinmetz, K., Vegetables, fruit and phytoestrogens as preventive agents, IARC Sci Publ., 139, 61-90, 1996.
154. Barnes, S., Phytoestrogens and breast cancer, Baillieres Clin. Endocrinol. Metab., 12, 559-579, 1998.
155. Diel, P., Smolnikar, K., Schulz, T., Laudenbach-Leschowski, U., Michna, H., and Vollmer, G., Phytoestrogens and carcinogenesis-differential effects of genistein in experimental models of normal and malignant rat endometrium, Hum. Reprod., 16, 997-1006, 2001.
156. Lian, Z., Niwa, K., Tagami, K., Hashimoto, M., Gao, J., Yokoyama, Y., Mori, H., and Tamaya, T., Preventive effects of isoflavones, genistein and daidzein, on estradiol-17beta-related endometrial carcinogenesis in mice, Jpn. J. Cancer Res., 92, 726-734, 2001.
157. Chhabra, S.K. and Yang, C.S., Tea and prostate cancer, Epidemiol. Rev., 23, 106-109, 2001.
158. Hong, J., Smith, T.J., Ho, C.T., August, D.A., and Yang, C.S., Effects of purified green and black tea polyphenols on cyclooxygenase- and lipoxygenase-dependent metabolism of arachidonic acid in human colon mucosa and colon tumor tissues, Biochem. Pharmacol., 62, 1175-1183, 2001.
159. Yang, C.S., Prabhu, S., and Landau, J., Prevention of carcinogenesis by tea polyphenols, Drug Metab. Rev., 33, 237-253, 2001.
160. Yang, C.S., Inhibition of carcinogenesis and toxicity by dietary constituents, Adv. Exp. Med. Biol., 500, 541-550, 2001.
161. Yang, C.S., Yang, G.Y., Chung, J.Y., Lee, M.J., and Li, C., Tea and tea polyphenols in cancer prevention, Adv. Exp. Med. Biol., 492, 39-53, 2001.
162. Lamartiniere, C.A., Moore, J.B., Brown, N.M., Thompson, R., Hardin, M.J., and Barnes, S., Genistein suppresses mammary cancer in rats, Carcinogenesis, 16, 2833-2840, 1995.